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Abstract 
Tuberculosis is a major global health hazard.  The search for new anti-mycobacterials has focused on 
such as screening combinational chemistry libraries or designing chemicals to target pre-defined 
pockets of essential bacterial proteins. The relative inefficiencies of these have led to a reappraisal of 
natural products for new anti-mycobacterial drug leads. However, progress has been limited, we 
suggest through a failure in many cases to define the drug target and optimise the hits using this 
information. We highlight methods of target discovery needed to develop a drug into a candidate for 
clinical trials. We incorporate these into suggested analysis pipelines which could inform the research 
strategies to accelerate the development of new drug leads from natural products. 
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1. Natural Products: Moving back to the forefront of anti-mycobacterial target discovery 
 
Tuberculosis (TB) is the world’s leading cause of death from infectious disease, causing an estimated 
1.4 million deaths in 2015[1]. This effectively represents a reverse of trends seen during the middle 
years of the 20
th
 Century when antibiotics, developed from the 1940s on, appeared to be effective in 
controlling the disease. However, over the last two decades TB is again a major public health hazard 
with the appearance of drug-resistant strains of TB (DR-TB), multidrug-resistant TB (MDR-TB), 
extensively drug-resistant TB (XDR-TB) and more recently strains resistant to all the anti-tubercular 
chemotherapies[2]. This situation has arisen for a great extent due to the complex drug therapy regime 
used for TB which reduces patient compliance and adherence to prescribed medication. Thus, anti-
tubercular chemotherapy consists of at least a 6-month drug regimen involving an initial two month 
phase of four agents (isoniazid, rifampicin, pyrazinamide and ethambutol) followed by an additional 
four months with isoniazid and rifampicin[3,4].  
 
MDR-TB is resistant to rifampicin and isoniazid, the most effective anti-tuberculous drugs. XDR-TB 
strains are resistant to at least rifampicin and isoniazid but also fluoroquinolones and to, at least, one 
of the injectable drugs; capreomycin, kanamycin or amikacin. Treatment of MDR-TB consists of a 2-
year therapy with a combination of four to six first- and second-line anti-tubercular drugs[5]. TB 
control is therefore contingent on the development of new drugs and in the past decade there have 
been major efforts made in this area. There is also a need for new drugs that act quickly, giving fewer 
opportunities for the TB-causing organism to develop resistance. Any new drugs also need to be 
inexpensive to produce, so that it can be widely adopted in countries outside of the first world. Due to 
renewed research and development efforts, bedaquiline, a diarylquinolone, became the first anti-TB 
drug approved by the United States Food and Drug Administration (FDA) in more than 40 years.[6] 
Additionally, innovative methodologies have allowed the development of more effective therapies, 
the ‘revitalization’ of old drugs, re-use of drugs in different contexts, and the reduction of drugs 
rejected due to their toxicity profile. A vitally important aspect of research leading to new drugs or 
use of existing drugs is a requirement to fully comprehend, at least as far as possible, their 
mechanisms of action and, this way, prevent problems with toxicity at the early stages of clinical 
trials. 
 
In the early part of the last century, research into natural products was prominent in the search for new 
drug leads. Indeed, the attractiveness of natural products is obvious considering they reflect the 
outcome of evolutionary pressures acting on genomes to produce bioactives to serve many roles 
including anti-microbial[7]. Streptomycin, isolated from actino-bacterium Streptomyces griseus, is an 
important example and on first introduction was as a standard treatment against TB. However, with 
the emergence of DR-TB and its increased prevalence with the onset of human immunodeficiency 
virus/acquired immune deficiency syndrome (HIV/AIDS), streptomycin has been replaced by other 
therapies. Streptomycin is also problematic due to its oto- and nephrotoxicity with prolonged 
therapies.[8] With the advent of combinatorial chemistry and high-through-put screening strategies, 
drug discovery focusing on natural products became less popular. It was thought that screening vast 
combinatorial libraries would speed up the development process by eliminating lengthy natural 
product identification and often complex synthesis programmes; the poor hit rate though of the 
combinatorial approach and low diversity of the libraries led to most big Pharma companies 
abandoning this approach and looking for new and better ways to explore natural products. As a result 
of the combinatorial library focus, very few antibiotics, derived or based on natural products, had 
been approved in the past two decades by the FDA. 
 
The importance of a good anti-mycobacterial therapy does not reside only on drug potency and safety, 
but also in some key features that targets should display. Kana et al. defines the “ideal” target as a 
macromolecule that 1) acts in the growth, survival and latency of the bacteria, 2) regulates crucial 
checkpoints of bacterial metabolism, 3) has a low tolerance for mutation and 4) is found at targetable 
locations within the cell. Additionally, the drug target must not show such similarity with human 
homologues enough to compromise the drug safety[9]. To meet such requirements many groups 
favour an approach where drugs are derived to known mycobacterial proteins. Besides avoiding the 
possibility of new, unexpected targets being defined, this approach could be flawed since it does not 
consider the cell environment as essential to the drugs mode of action. Thus, several details are not 
evaluated; for example the pharmacokinetics of drug internalization by the mycobacteria, innate 
resistance mechanisms (e.g. efflux pumps) and the physico-chemical properties of both bacteria and 
compound. Consequently, potent inhibitors of a specific target can display unsatisfactory values of in 
vitro minimum inhibitory concentration (MIC) against Mycobacterium species[10]. One example of 
target-based drug discovery that has recently failed is isocitrate lyase, a key enzyme within the 
glyoxylate shunt pathway. This enzyme was suggested as a suitable target since it is essential to the 
growth and virulence of M. tuberculosis in both acute and chronic phases of infection.[11] This work 
was discontinued most likely to the target active site being “shallow” and  lack of hydrophobic 
patches that could be targets for inhibitors[12]. None of the drugs that are currently in clinical trials 
have arisen following a target-to-drug approach instead these have tended to follow drug-to-target 
strategies based on whole cell-based screenings[13]. 
 
It is against this background that natural product discovery based on whole-cell screenings have 
become a viable strategy to provide druggable molecules. However, this strategy should be combined 
with innovative ‘-omics’ technologies, chemical biology and genetics which have made possible the 
discovery of new drug and target leads[14]. This is especially useful in the search for new agents 
against M. tuberculosis where natural products have assumed a prominent role[15]. The potential of 
natural products as anti-mycobacterial drug leads lies in their intrinsic cell permeability and structural, 
functional and stereochemical diversity, that provide unique scaffolds for further drug optimisation 
towards increased potency and selectivity[16,17]. Moreover, new natural products could be a useful 
tool to unveil the role of several proteins which are transcribed from the M. tuberculosis genome but 
whose functions are unknown[18,19]. 
 
These points notwithstanding, the recent failures to take forward natural products or their derived 
synthetics needs to be recognised and the underlying causes identified. We suggest that these arise 
through incomplete workflow methodologies which massively affect further development of an anti-
tubercular drug. A cursory glance at the literature will show many examples of anti-mycobacterial 
activity being detected in a natural product but these observations are not further characterised and 
can be thought of as effectively useless from the perspective of defining a new drug lead. In 
particular, the unequivocal identification of the biological target coupled with a clear mechanism of 
action of the bioactive is often not done[20]. This is essential to allow the reduction in the number of 
microbial “off-targets” and toxicity to human systems and so leading to the development of potent and 
safe drugs against M. tuberculosis.  
 
This review will focus on anti-mycobacterial target discovery methodologies and highlight examples 
of “best practice” where natural product research has included optimisation of target identification and 
validation steps [21] (Table 1). In doing so, it will identify potential pipelines for target discovery and 
validation which could inform research strategies based on natural products.  For readers wishing to 
consider only the discovery of anti-mycobacterial natural products we recommend the following 
review articles[22–24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1:  Methods used for the targeting and optimisation of anti-mycobacterial drug leads derived from natural 
products. 
 
a) Against M. smegmatis. 
b) IC50 against MptpB was 7.3-8 μM. 
 
 
2. Methodological options for target discovery 
2.1. Biochemical approaches  
The “classical” approach to target discovery and validation aims to assess biochemical differences 
arising following treatment with the natural product. Such change could arise from the perturbation of 
enzymatic activities and these approaches can give valuable insights of the mode of action and target. 
Putative mycobacterial targets that have been explored using this strategy can be classified according 
to the pathway they affect. Thus, notable biochemical targets have proven to be in peptidoglycan 
biosynthesis, arabinogalactan and lipoarabinomanan biosynthesis, mycolic acids biosynthesis, 
shikimate pathway, pantothenate biosynthesis, biotine pathway, glyoxylate shunt pathway and DNA 
metabolism[25,26]. 
 
Scientists following such biochemical approaches have provided some essential insights to a robust, 
multifaceted pipeline that can yield some potentially druggable anti-mycobacterials. Thiolactomycin 
(TLM) (Fig.1) was isolated from Nocardia sp., and displays a MIC of 25 μg/mL against M. 
   Target discovery strategy Drug optimisation 
Natural product 
MIC 
 (mM) 
Target 
Biochemical 
approaches 
Whole-cell 
based 
screening 
Mutant 
generation 
and WGS 
Affinity probes 
and proteomics 
Genomic 
library 
screenings 
Crystal 
structure 
Analogues 
synthesis 
and SAR 
Docking 
studies 
Agelasine D 1.98 a) BCG3185c     X    
Agrimophol 12.5 Rv3852  X  X     
Berberine 74.3 Ftsz X      X X 
Brunsvicamides b) MptpB X X       
Cyclomarin A 0.30 ClpC1  X  X     
Ecumicin 0.14 ClpC1  X X X  X   
Halicyclamine A 13.5 DedA     X    
Lassomycin 
0.41 - 
1.65 
ClpC1 X X      X 
Pyridomycin 0.72 InhA  X X   X   
Thiolactomycin 118.9 
KasA, 
KasB 
X X     X X 
Trichoderin 0.10 
ATP 
synthase 
    X    
tuberculosis[27]. Despite the quite high MIC, TLM’s physicochemical properties, its low cytotoxicity 
in ex vivo macrophage models and high in vivo availability , are features that encouraged its further 
development[27–29]. Several studies have revealed that both β-ketoacyl-ACP synthases I / II and 
acetyl coenzyme-A (CoA) were targets of TLM in E. coli[30]. Based on the incorporation of 
radiolabelled isotopes into fatty acids and mycolic acid metabolism, it was concluded that TLM 
reversibly inhibits the synthesis of both fatty acids and mycolic acids with a high selectivity (at 0.75 
μg/mL) for Fas-II β-ketoacyl-ACP synthase[31]. Kremer et al. over-expressed KasA and KasB, two 
synthases belonging to the  Fas-II family, to validate these as targets of TLM[32]. Several analogues 
of TLM, either in racemic mixtures or as pure enantiomers, have been synthesised and tested in vitro 
against M. tuberculosis[33]. When considered together, these TLM analogues will contribute to 
structure-activity relationship studies, vital for TLM optimisation. Thus, a dataset of 40 TLM 
analogues, β-ketoacyl-ACP synthase III (mtFabH) inhibitors were subjected to a 3D-quantitative 
structure-activity relationship (3D-QSAR) analysis. The derived QSAR model and associated docking 
studies is informing our understanding of the mechanism of TLM as a mtFabH inhibitor[34]. 
 
Brunsvicamides are cyclic hexapeptides that were first isolated from the cyanobacterium Trychonema. 
These, especially Brunsvicamide B and C (Fig. 1), were shown to target protein tyrosine phosphatase 
B (MptpB) which is an essential virulence factor of mycobacterial species. The activity of these 
compounds were successfully assessed against a range of protein phosphatases where MptpB showed 
an IC50 of 7.3 μM[35]. The characterisation of MptpB as the target directly led to the identification of 
novel synthetic inhibitors of this protein using high throughput screens[36]. These, along with diverse 
natural variants could provide sufficient chemical diversity to perform SAR studies of MptpB and 
therefore new treatments for tuberculosis[37]. 
 
Another example is berberine (Fig. 1), a natural benzylisoquinoline alkaloid obtained from the plant 
genus Berberis. This was found to be active against M. smegmatis and MDR-TB at 25 μg/mL[38]. 
Studies which included in silico molecular docking analysis revealed the target  to be a protein called  
Ftsz[39]. This protein forms a ring to aid in the formation of the septum between dividing bacterial 
cells. Additionally proper ordering of the septum is dependent on FtsZ GTPase activity. Berberine 
was found to inhibit Fstz ring assembly in a dose-dependent manner by a real-time light-scattering 
assay and GTPase activity using a GTP hydrolysis assay. The binding between Ftsz and berberine 
were confirmed by isothermal titration calorimetry. The clear identification of this protein as the 
berberine target led directly to the derivation of berberine analogues aimed at a structure-activity 
relationship analysis using 2D- and 3D-QSAR[40,41]. The relative success of these analyses will be 
an important determinant in the optimisation of berberine as a potential drug.  
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Fig. 1. Chemical structures of thiolactomycin, brunsvicamide B and C and berberine.  
 
 
2.2. Genomic-based approaches  
 Some of the more recent approaches used in drug target discovery take advantage of the great 
advances in genome sequencing capabilities. These encompass a wide variety of approaches including 
transcriptomic analyses and DNA-protein binding studies based on chromatin immunoprecipitation 
(ChIP). In this approach antibodies are used to enrich for particular chromatin components and the 
relative amount of associated DNA sequences can reveal epigenetic control points[42]. 
 
Considering genomic approaches to search for anti-mycobacterials targets, some are based on 
screening genomic libraries for clones that could confer tolerance when expressed in heterologous 
hosts. This methodology was used to identify the targets for halicyclamine A, trichoderin A and 
agelasine D, three natural products derived from the marine sponges Haliclona sp. 05A08, 
Trichoderma sp. and the genus Agelas, respectively (Fig. 2)[43–45]. Genomic cosmid libraries were 
constructed from strains of M. smegmatis and M. bovis BCG which exhibited spontaneous resistance 
to one of the above compounds and each cosmid was introduced into a susceptible strain. Cosmids 
with derived alleles that are mutated in the target(s) could increase the minimum inhibitory 
concentration (MIC) required to affect the recipient mycobacterial strain. By following this strategy, 
DedA was identified as the target of halicyclamine A and BCG3185c as the target for agelasine 
D[46,47], but unfortunately, these results were not validated by other approaches. In contrast, cosmid 
screening suggested that trichoderin A targeted ATP synthase, which was validated by measurements 
of the ATP content in M. bovis BCG[48]. The first total synthesis of trichoderin A has recently been 
described and this will be essential in structure-activity relationship (SAR) studies[49]. 
 
Moving beyond cosmid library screening, whole-genome sequencing (WGS) analyses are assuming a 
very significant role in target discovery by (for example) identifying distinctive genes present only 
within Mycobacterium. However, this powerful approach needs to be carefully used as suggested 
targets can be intractable, non-essential or undrugabble[50]. Thus, we suggest that the genomic 
information should be used within a combined methodology pipeline complemented by validation 
techniques based on target discovery on tuberculosis[13]. This pipeline could be as follows. Firstly, 
the MIC must be confirmed using whole mycobacterial cell based in vitro screens. These will inform 
what concentrations of natural target to use in suggestive rounds of culturing with the aim of deriving 
variants which exhibit resistance. Such resistance could arise from target over-expression of deletion, 
transcriptional or translational disruption or mutation of a key motif. Bacterial DNA from mutants that 
are resistant to high concentrations of the specific molecule is extracted and sequenced, aiming at 
confirmation of the mutational site[51]. 
 
This seemingly straight-forward strategy may be confounded by the up-regulation of bacterial defence 
mechanisms such as efflux pumps. Indeed, increased activity of efflux pumps may be a bacterial 
response to the xenometabolite, rather than direct genetic alteration of operons encoding mutations in 
the efflux pumps. In this context, it is relevant that antibiotic resistance clinical isolates do not show 
any mutations in the genes and regulators of bacterial efflux systems. As a result the efflux pumps can 
provide “false-positives” i.e. strains where there have been no mutations events linked to the bioactive 
target. Thus, Ioerger et al. suggested the inclusion of an efflux-pump inhibitor then screening for 
mycobacterial resistance to any bioactive[51]. Suitable efflux-pump inhibitors could be natural 
products such as reserpine or verapamil[52]. 
 
The discovery of the recent natural product lead against TB, pyridomycin (Fig. 2), is an example of a 
complete and validated target discovery based research, which included genomic analyses. 
Pyridomycin, was isolated from Dactylosporangium fulvum and Streptomyces pyridomyceticus, and 
exhibited a MIC of 0.39 μg/mL against M. tuberculosis. Hartkoorn and his colleagues identified InhA, 
a NADH-dependent enoyl-Acyl-Carrier-Protein as the principal target of pyridomycin following 
WGS of a resistant mutant colony of M. tuberculosis. Although InhA is also the target of isoniazid, 
pyridomycin behaves as a competitive inhibitor of this protein as shown by its activity against 
isoniazid-resistant clinical isolates. To validate the target, wild-type inhA and the mutant form was 
over-expressed in M. tuberculosis H37Rv and this allowed the steady state kinetics and susceptibility 
to isoniazid and pyridomycin to be accurately measured[53]. 
 
Insights on lassomycin (Fig. 2) mode of action were also made using a WGS approach. Lassomycin 
was isolated from Lentzea kentuckyensis spp. IO0009804 and exhibits MIC ranging between 0.41 to 
1.65 μM against M. tuberculosis, MDR-TB and XDR-TB strains. WGS identified mutations in the 
clpc1 gene in six spontaneous lassomycin-resistant M. tuberculosis colonies. This gene encodes the 
ClpC1 subunit of the hexameric ATPase complex and this target was validated by measuring ATP 
hydrolysis and ATP-dependent protein breakdown by ClpP1P2. To understand the mechanism of 
action of lassomycin, a molecular docking approach was performed, focussing on the mutated sites 
revealed by WGS[54]. This study also highlighted the requirement to sequence multiple spontaneous 
mutants in order to demonstrate consistent genetic alterations in a putative target as against a 
background of genetic changes that would be unlinked to the resistance mechanism. Such a strategy 
could also reveal mechanisms based on multiple components acting synergistically. Thus, the 
increasing the number of mutant sequences would increase the likelihood of any inferred resistance 
mechanism being correct. Thus, six mutants were sequenced to suggest the lassomycin target but the 
actual number sequenced in other projects could be limited by financial resources. 
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Fig. 2. Chemical structures of halicyclamine A, trichoderin A, agelasine D, pyridomycin and 
lassomycin. 
 
 
 
2.3. Proteomic approaches 
 In situ identification of protein-molecule interactions is another valuable tool for the discovery of 
targets in a native cellular environment. These are based on advances in organic chemistry that have 
permited the detection of target and off-target interactions by the modification of key “activatable” 
groups of active molecules[55,56]. Chemical proteomics is based on the manipulation of a natural 
product of interest with a tag, normally a terminal alkyne, azide or cyclopropene, which will react via 
bio-orthogonal ‘click’ chemistry reaction with a fluorophore or affinity label. This reaction will occur 
after cells, previously incubated with the natural product, are lysed. These terminal groups are small 
enough to not interfere negatively with the molecular binding between the target and the reactive site 
on the natural product. Biotin or a fluorophore can be directly attached to the natural product, instead 
of the tag, if permitted by their reactivity. The result of the reaction between the natural product and 
the fluorophore or affinity label can be analysed by SDS-PAGE with in-gel fluorescence or LC-MS 
proteomics[57]. 
 
An affinity-based method was used to discover the target of agrimophol (Fig. 3), a phloroglucinol 
from Agrimonia pilosa, which is a plant used in traditional Chinese medicine. Interestingly, this 
strategy was followed when no agrimophol-resistant mutants were obtained. Whole-cell based screens 
against M. tuberculosis found that agrimophol was able to inhibit pH homeostasis. A click-chemistry 
reaction was carried out to produce a biotinylated triazole and proteins were fractionated by SDS-
PAGE. Following screening with the pre-biotinylated probe a1b, the M. tuberculosis protein Rv3852; 
whose function is unclear, was suggested as the target of agrimophol; a conclusion that was further 
validated by protein mass fingerprinting[58]. A similar methodology was used to discover the target 
of cyclomarin A (Fig. 3) produced by a marine bacterium (Streptomyces sp.)[59]. This is a cyclic 
peptide, identified from a whole-cell screening, and has MICs of 0.3 and 2.5 μM against M. 
tuberculosis in culture broth and in human-derived macrophages, respectively[59]. In attempting the 
identification of the cyclomarin A target in M. tuberculosis, no spontaneous resistant mutants could be 
isolated, Therefore, a proteomic approach appeared to be an appropriate alternative method. Here, 
cyclomarin A was linked to sepharose beads and co-incubated with a M. bovis BCG cell lysate to 
enrich for the interacting target. The mixture was then separated using SDS-PAGE gels to reveal 
ClpC1 was the major cyclomarin A interactor[59]. With the target now defined follow on studies 
revealed the co-crystal structure of the complex cyclomarin A-ClpC1. This will be indispensable to 
the design and synthesis of new anti-mycobacterials that target ClpC1[60]. 
 
Another strategy that can be used to identify targets from natural products is DARTS (drug affinity 
responsive target stability). It is based on the protective action against proteolysis conferred through 
target-protein interactions. Comparison of the degradation patterns in natural product interacting 
(“protected”) samples versus “unprotected” controls can be used to suggest protein targets. This 
technique is known to be fast and avoids any costly structural modifications on the natural product as 
demanded in the techniques described previously.  
 
Ecumicin (Fig. 3), a macrocyclic tridecapeptide isolated from Nonomuraea sp. MJM5123, was 
discovered following high-throughput screening from different extracts of several actinomycetes.[61] 
It was highly active against M. tuberculosis, (MIC 0.26 μg/mL) and against strains resistant to 
streptomycin, rifampicin and cycloserine[61]  but its further development required definition of its 
mode of action within the bacteria.  Initially, the genomic DNA of ecumicin-resistant strains of M. 
tuberculosis were sequenced and compared with the corresponding wild-type strain. As with 
agrimophol ClpC1, was one of the targets found and was further validated using a proteomics-based 
test for drug affinity responsive target stability (DARTS).  Thus, ecumicin was able to protect ClpC1 
from nonspecific proteolytic degradation in wild-type M. tuberculosis but not in the mutated form. 
Additional validation was made after LC-MS analysis of the excised band. In a logical, and important 
further step, Gao et al co-crystallised ecumicin docked with ClpC1 which provided crucial 
information on the protein pocket required for interaction with the natural product and hence its 
molecular mechanisms of action. This information has facilitated the informed design of synthetic 
derivatives of ecumicin that could be more effective antibiotics[62]. 
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Fig. 3 Chemical structures of agrimophol, cyclomarin A and ecumicin. 
3. Computational chemistry strategies to inform and optimise anti-mycobacterial natural 
products  
 
X-ray crystallography can provide important insights on specific binding between drug and target 
through high-resolution 3D structural data. For instance, X-rays were used to confirm that N-terminus 
of ClpCq bound lassomycin via positively charged guanidium groups. Docking studies showed that 
the N-terminal Gln17 was the major interacting residue through hydrogen binding. Moreover, 
lassomycin binding was reduced when Gln17 was mutated to Arg- or His[54]. 
The widespread use of X-ray crystallography has led to a rapid increase in three-dimensional protein 
structures suitable to use in in silico methods for hit identification and lead optimization. In addition 
to the computational chemistry methodologies that have been successfully applied on natural products 
to optimise drugs with antimycobacterial activity, other drug design techniques show considerable 
promise. Fragment-based de novo drug design, for instance, has enabled the re-designing of 
molecules, in a drug-target environment. This has led to the production of more active synthetic 
molecules based on the original scaffold and interactions[63]. However, this method has never been 
used in drug design of natural products against tuberculosis targets[64]. 
Different techniques in computational chemistry now also play important roles in optimisation of a 
drug where previous research can be considered to only have provided a scaffold for further 
development. Once again natural products are often not taken forward to this important stage as no 
target is identified and validated and so will fail in the advancing the druggability of any identified 
bioactive. Thus, computerised approaches allow the visualisation and analysis of three-dimensional 
structures of the bioactive molecule and the target protein and their interactions. Based on these, it is 
possible to use virtual screening approaches to design derivatives, which allow better interaction 
between target and drug without altering its physical and chemical properties, assuring the drug is 
effective and not toxic and making synthesis more efficient. This was successfully applied with the 
generation and screening of new InhA inhibitors in silico[65]. 
Although these approaches are powerful, they seldom can function ex nihilo i.e. design a drug based 
only on knowledge of the protein target pocket. Given this, natural product libraries play an important 
role in screening as they present a wide-ranging diversity of scaffolds complemented with a range of 
structural and functional features[66]. 
 
4. Future perspective 
The examples given above have highlighted several approaches used to exploit natural products as 
new anti-mycobacterial drugs. Although these present impressive progress, none has yet achieved the 
status of a commercially available drug. This reflects the relative ease that anti-mycobacterial natural 
products can be identified but is not matched by strategies where their targets are quickly defined. 
Without this, the value of a natural product as a drug lead cannot be assessed and, if suitable, further 
optimised. However, current research has also furnished approaches which can be rationalised into a 
robust discovery pipeline; often based on the use of the latest genomic and computational platforms 
(Fig. 4). It should be noted that key steps in the pipeline, target discovery and lead optimisation, 
encompass many approaches. Particularly with target discovery, adoption of multiple approaches at 
each step will undoubtedly increase the probability of successful definition of the targets, and not 
“off-targets” for anti-mycobacterial activity. Therefore, the results of multiple strategies should be 
complementary and mutually confirmatory. This would also represent an efficient use of resources 
since the process of obtaining the natural products with their typically low yields, sometimes 
difficulty in confirming structures and complex/expensive synthetic routes, can impede progress. 
Given these points, research groups are urged to follow such a strategy to increase the probability of 
success; i.e. leading to drug candidates. This would allow the power of natural selection acting on 
natural products to be more effectively exploited in the search for new anti-mycobacterials.  
 
 
 
  
Fig. 4. Strategies for anti-mycobacterial discovery pipeline from natural products. MIC, minimal inhibitory 
concentration; MBC, minimal bactericidal concentration.  
 
 
Executive summary 
Difficulties of target deconvolution 
- High throughput screenings of combinatorial libraries for target discovery have a poor hit rate 
-  Natural products yield scaffolds that can be used as tools towards novel targets discovery 
Target discovery from natural products 
- Natural products based research programmes normally do not follow a complete pipeline of target 
discovery and validation 
- Whole-cell based screenings combined with ‘-omics’ technologies make possible the discovery of 
new targets from new drug leads 
- Use of ‘-omics’ allows small amounts of sample to discover of new targets  
- Target discovery allows the consequent rational optimisation of compounds or total synthesis by de 
novo techniques 
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